J. Walz to Prognosis
This is a "connection" page, showing publications J. Walz has written about Prognosis.
Connection Strength
0.067
-
Manafi-Farid R, Harsini S, Saidi B, Ahmadzadehfar H, Herrmann K, Briganti A, Walz J, Beheshti M. Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review. Eur J Nucl Med Mol Imaging. 2021 11; 48(12):4028-4041.
Score: 0.032
-
Tosco L, Laenen A, Briganti A, Gontero P, Karnes RJ, Bastian PJ, Chlosta P, Claessens F, Chun FK, Everaerts W, Gratzke C, Albersen M, Graefen M, Kneitz B, Marchioro G, Salas RS, Tombal B, Van den Broeck T, Van Der Poel H, Walz J, De Meerleer G, Bossi A, Haustermans K, Van Poppel H, Spahn M, Joniau S. The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis. Eur Urol Focus. 2018 04; 4(3):369-375.
Score: 0.024
-
Gallina A, Jeldres C, Chun FK, Shariat SF, Briganti A, Walz J, Roehrborn CG, Saad F, Huland H, Graefen M, Montorsi F, Karakiewicz PI. Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL. Eur Urol. 2007 Nov; 52(5):1374-80.
Score: 0.012